64 Results

People

  1. Lesokhin
    Lesokhin
  2. Derkach
    Derkach
  3. Shah
    Shah
  4. Hassoun
    Hassoun
  5. Mailankody
    Mailankody
  6. Korde
    Korde
  7. Tan
    Tan
  8. Giralt
    Giralt
  9. Hultcrantz
    Hultcrantz
  10. Shah
    Shah

Groups

  1. Center for Hematologic Malignancies (64)
  2. Department of Medicine (64)
  3. Hematologic Malignancies Research (64)
  4. Hematologic Malignancies, Division of (64)
  5. Myeloma (64)
  6. Population Sciences Research Program (64)
  7. Biostatistics Service (62)
  8. Epidemiology and Biostatistics (62)
  9. Sloan Kettering Institute Postdocs (57)
  10. CTCR Scholars (55)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Alexander Lesokhin"
  4. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (15)
  3. Research Letter (4)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (64)
  2. Department of Medicine (64)
  3. Hematologic Malignancies Research (64)
  4. Hematologic Malignancies, Division of (64)
  5. Myeloma (64)
  6. Population Sciences Research Program (64)

More Groups

People
  1. Alexander Lesokhin (64)
  2. Andriy Derkach (57)
  3. Urvi Shah (55)
  4. Malin Hultcrantz (54)
  5. Hani Hassoun (53)
  6. Sham Mailankody (53)

More People

Years
  1. 2024 (2)
  2. 2023 (20)
  3. 2022 (20)
  4. 2021 (10)
  5. 2020 (6)
  6. 2019 (1)

More Years

Publications
  1. Blood (25)
  2. Clinical Lymphoma, Myeloma and Leukemia (14)
  3. Journal of Clinical Oncology (6)
  4. Blood Advances (3)
  5. American Journal of Hematology (2)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (28)
  2. Elsevier Inc. (15)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (4)
  5. American Association for Cancer Research (3)
  6. John Wiley & Sons, Inc. (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study
    Research Letter

    Castro, F.; Parikh, R.; Eustaquio, J. C.; Derkach, A.; Joseph, J. M.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Leukemia (2024)

    Fulltext@MSK | Save
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save